Vertex Pharmaceuticals Incorporated
US ˙ NasdaqGS ˙ US92532F1003

SecurityVRTX / Vertex Pharmaceuticals Incorporated
InstitutionBLACKROCK ADVANTAGE GLOBAL FUND, INC. - BLACKROCK ADVANTAGE GLOBAL FUND, INC. Investor A
Latest Disclosed Ownership896 shares
Latest Disclosed Value $ 398,899
BLACKROCK ADVANTAGE GLOBAL FUND, INC. - BLACKROCK ADVANTAGE GLOBAL FUND, INC. Investor A reports 13.43% decrease in ownership of VRTX / Vertex Pharmaceuticals Incorporated

On August 28, 2025 - BLACKROCK ADVANTAGE GLOBAL FUND, INC. - BLACKROCK ADVANTAGE GLOBAL FUND, INC. Investor A filed a NPORT-P form disclosing ownership of 896 shares of Vertex Pharmaceuticals Incorporated (US:VRTX) valued at $398,899 USD as of June 30, 2025. The entity filed a previous NPORT-P on May 28, 2025 disclosing 1,035 shares of Vertex Pharmaceuticals Incorporated. This represents a change in shares of -13.43% during the quarter. The current value of the position is $385,540 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2025-08-28 2025-06-30 NP Vertex Pharmaceuticals EC US92532F1003 896 -139 -13.43 399 -20.56 0.0843
2025-05-28 2025-03-31 NP Vertex Pharmaceuticals EC US92532F1003 1,035 283 37.63 502 65.89 0.1127
2025-02-25 2024-12-31 NP Vertex Pharmaceuticals EC US92532F1003 752 -131 -14.84 303 -26.34 0.0813
2024-11-26 2024-09-30 NP Vertex Pharmaceuticals EC US92532F1003 883 -812 -47.91 411 -48.36 0.1049
2024-08-26 2024-06-30 NP Vertex Pharmaceuticals EC US92532F1003 1,695 -61 -3.47 794 8.17 0.2077
2024-05-28 2024-03-31 NP Vertex Pharmaceuticals EC US92532F1003 1,756 273 18.41 734 21.72 0.1917
2024-02-26 2023-12-31 NP Vertex Pharmaceuticals EC US92532F1003 1,483 -539 -26.66 603 -14.22 0.1591
2023-11-28 2023-09-30 NP Vertex Pharmaceuticals EC US92532F1003 2,022 -108 -5.07 703 -6.14 0.1918
2023-08-25 2023-06-30 NP Vertex Pharmaceuticals EC US92532F1003 2,130 -60 -2.74 750 8.55 0.1902
2023-05-26 2023-03-31 NP Vertex Pharmaceuticals EC US92532F1003 2,190 -83 -3.65 690 5.18 0.1794
2023-02-24 2022-12-31 NP Vertex Pharmaceuticals EC US92532F1003 2,273 16 0.71 656 0.46 0.1782
2022-11-25 2022-09-30 NP Vertex Pharmaceuticals EC US92532F1003 2,257 1,168 107.25 653 113.40 0.1915
2022-08-25 2022-06-30 NP Vertex Pharmaceuticals EC US92532F1003 1,089 289 36.12 307 47.12 0.0802
2022-05-26 2022-03-31 NP Vertex Pharmaceuticals EC US92532F1003 800 -1,048 -56.71 209 -48.64 0.0453
2022-02-25 2021-12-31 NP Vertex Pharmaceuticals EC US92532F1003 1,848 1,310 243.49 406 317.53 0.0820
2021-11-24 2021-09-30 NP Vertex Pharmaceuticals EC US92532F1003 538 -2,500 -82.29 98 -84.15 0.0208
2021-08-26 2021-06-30 NP Vertex Pharmaceuticals EC US92532F1003 3,038 268 9.68 613 2.86 0.1245
2021-05-27 2021-03-31 NP Vertex Pharmaceuticals EC US92532F1003 2,770 41 1.50 595 -7.61 0.1378
2021-02-25 2020-12-31 NP Vertex Pharmaceuticals EC US92532F1003 2,729 2,163 382.16 645 318.18 0.1530
2020-11-25 2020-09-30 NP Vertex Pharmaceuticals EC US92532F1003 566 -154 -21.39 154 -26.32 0.0402
2020-08-27 2020-06-30 NP Vertex Pharmaceuticals EC US92532F1003 720 -1,310 -64.53 209 -56.73 0.0565
2020-06-01 2020-03-31 NP Vertex Pharmaceuticals EC US92532F1003 2,030 -154 -7.05 483 1.05 0.1522
2020-02-27 2019-12-31 NP Vertex Pharmaceuticals EC 92532F100 2,184 -76 -3.36 478 25.13 0.1107
2019-11-27 2019-09-30 NP Vertex Pharmaceuticals EC US92532F1003 2,260 2,260 383 0.0905
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.